The strength of this gas exchange-derived variable stands on the well-recognized pathophysiological background, a documented predictive superiority compared with peak VO 2 along with the ability to stratify the risk of events even in heart failure patients with still preserved peak VO 2 ( > 18 ml/min per kg). 3 In the last five years, a series of reports have been focusing on how this indicator performs in predicting outcome in heart failure with preserved ejection fraction (HFpEF) [4] [5] [6] [7] with a very recent extension to the analyses of the heart failure midrange ejection fraction (HFmrEF) subset. 4, 5 An increased VE/VCO 2 slope depends on a number of complex pathways that may be broadly summarized under the occurrence of a deregulation of cardiorespiratory reflex control with impaired chemoreceptor sensitivity and development of intrinsic pulmonary vascular and non-vascular pathology leading to vasoconstriction, thickening of the interstitial space and lung congestion. 8 These all impair to various extents ventilation (V)/perfusion (Q) matching mainly secondary to the initial trigger, that is, the increase in pulmonary capillary wedge pressure and subsequent elevation in pulmonary vascular resistances. 7 The former mechanisms driven by an impaired PaCO 2 control seem predominant in HFrEF 9,10 whilst an increased dead space due to inefficient perfusion is now considered as the main trigger in HFpEF. 11 Whereas the largest and long-lasting experience for HFrEF has led to definitive acquisition on the clinical advantages of measuring systematically the degree of ventilation inefficiency, data on HFpEF are discordant, [4] [5] [6] with the main amount of evidence pointing to a lack of prognostic prediction except for patients with documented pulmonary vascular disease. 12 The same appears to be true for HFmrEF. 5 In the present issue of the journal, Kato and coworkers 13 report an analysis, performed in a large number of heart failure patients, that may reconcile, in part, the controversial role of the VE/VCO 2 slope out of HFrEF, offering some insights into how to properly address the VE/VCO 2 slope in the right heart failure patient.
In 1501 participants, they addressed the role of the ageing process in the VE response to a maximal cardiopulmonary testing by dividing the population into three groups (<55, between 56 and 70, and >71 years) and performing a Cox multivariable regression analysis looking at the interaction of the VE/VCO 2 slope with age. Then, they analysed the results, distributing the population into three left ventricular ejection fraction subsets. Based on this double subdivision, results may provide a potential new route of interpretation of the conflicting results of previous reports.
Findings show that the VE/VCO 2 slope was higher in the older subset and the increase in VE/VCO 2 steepness occurred in all sub-ejection fraction categories in parallel with advancing age. Data confirm a high prognostic value for the VE/VCO 2 slope in HFrEF of any age range despite an age-dependent increase in hazard ratio. Conversely, in HFpEF, the VE/VCO 2 slope was prognostic only in the subset of older patients and no data analysis could be performed in HFmrEF because of the underpowered sample size.
Thus, it appears interesting to place in the right perspective the role of age and to restrict considerations to the analysis of HFpEF category.
The concept that there is an increasing VE/VCO 2 slope with ageing is well known but, up to now, it has not been put into practice in the prognostic studies performed by cardiopulmonary testing. In recent large scale studies performed in HFpEF the average age was much lower, 5, 6 around 10 years, than the average age of the subgroup in which the VE/VCO 2 slope was prognostic, explaining, at least in part, the discrepancy of the results.
Can we affirm that the changes in VE/VCO 2 slope observed by Kato et al. are dependent only upon age and not on heart failure per se? Likely not, because patients' symptoms and diagnostic criteria for heart failure were very well framed. Nonetheless, a control healthy, age-and sex-matched population would be helpful to dissect this point. Taking as reference nomograms proposed by Sun et al., 14 the expected VE/VCO 2 slope in subjects 70 years of age is 29 compared with the 37.6 in this report, which removes any doubt from the statistics.
A strength of the present study is the extension of the analysis to the role of body mass index, use of betablocker therapy and atrial fibrillation, especially in HFpEF. Although these factors emerged as important confounders in previous case series they did not in the present population.
Along with these considerations, the limit related to the lack of a full pulmonary haemodynamic evaluation clearly emerges, given that higher pulmonary vascular resistances during exercise result in the highest levels of VE/VCO 2 slope observed in HFpEF. 7 Were older patients also the subgroup which developed precapillary pulmonary hypertension during exercise? 15 This remains an unanswered question as well as a step forward to be clarified concerning the relative contribution of these mediators, especially in view of the recent findings by Wolsk et al. 16 showing that mean pulmonary capillary wedge pressure and pulmonary arterial pressure increase to considerably high levels during a maximal test in elderly healthy subjects.
Finally, data proposed by Kato et al. 13 reconcile with the reported discrepancies on the prognostic role of the VE/VCO 2 slope in HFpEF and warn to revisit the multifactorial reasons for an impaired VE efficiency in HFpEF by including ageing as a contributor in a potential longer disease history and a factor intrinsically affecting the pathogenesis of increased pulmonary pressures during exercise.
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